ACHV analyst estimates
Achieve Life Sciences (ACHV) analyst ratings, the average price target and its range, and every firm's latest call.
ACHV analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 29, 2026 | Stifel Nicolaus | Achieve Life Sciences initiated with a Buy at Stifel | $18.00 |
| Aug 13, 2026 | Morgan Stanley | Morgan Stanley Starts Achieve Life Sciences (ACHV) at Overweight | $13.00 |
| Aug 12, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Achieve Life Sciences (ACHV) | $12.00 |
| Aug 12, 2026 | Raymond James | Achieve Life Sciences price target lowered to $18 from $20 at Raymond James | $18.00 |
| Jun 26, 2026 | Raymond James | Achieve Life Sciences resumed with a Strong Buy at Raymond James | $20.00 |
| Apr 20, 2026 | Canaccord Genuity | Achieve Life Sciences initiated with a Buy at Canaccord | $13.00 |
| May 13, 2024 | Oppenheimer | Achieve Life Sciences (ACHV) PT Lowered to $11 at Oppenheimer | $11.00 |
| Nov 16, 2022 | Maxim Group | Maxim Group Maintains Buy on Achieve Life Sciences, Lowers Price Target to $8 | $8.00 |
- 5 firms rate ACHV: 5 buy, 0 hold, 0 sell.
- The average price target is $15.25 from 4 analysts, from $12.00 to $18.00.
Updated 2026-11-03 11:31 UTC